
SUPPLEMENTARY MATERIALS


Supplementary Figure 1 Evaluation of epithelial and mesenchymal phenotypes in liver sections. [a] Immunofluorescence for S100a4 (in green) co-stained with CK-19 (in red). Nuclei are stained with DAPI. original magn. 40X, Scale bar = 20 μ m. [b-c] Immunofluorescence for vimentin or E-cadherin (in green) co-stained with desmin (in red). Nuclei are stained with DAPI. original magn. 40X, Scale bar = 20 μ m.


Supplementary Figure 2 Evaluation of hepatic inflammation in liver sections. Immunohistochemistry for F4/80 in liver sections, original magn. 20X, Scale bar = 100 μ m. Percentage of F4/80-positive area. *p<0.05 versus WT mice; #p<0.05 versus Mdr2-/- mice.


Supplementary Figure 3 Evaluation of angiogenesis in liver sections. Immunohistochemistry for VEGFA in liver sections, original magn. 20X, Scale bar = 100 μm. Percentage of VEGFA-positive area. *p<0.05 versus WT mice; #p<0.05 versus Mdr2^{-/-} mice.


Supplementary Figure 4 Evaluation of E-cadherin expression in human PSC patients. Immunofluorescence for E-cadherin (in green) co-stained with CK-19 (in red). Nuclei are stained with DAPI. original magn. 20X, Scale bar = $10 \mu m$.














Supplemental Table 1. List of qPCR primers

Gene	Species	Detected transcript	Source	
α-SMA	Mouse	NM_007392	QIAGEN	
Col1a1	Mouse	NM_007742	QIAGEN	
E-cadherin	Mouse	NM_009864	QIAGEN	
Fn1	Mouse	NM_010233	QIAGEN	
GAPDH	Mouse	NM_008084	QIAGEN	
N-cadherin	Mouse	NM_007664	QIAGEN	
p16	Mouse	NM_009877	QIAGEN	
p21	Mouse	NM_007669	QIAGEN	
S100a4	Mouse	NM_011311	QIAGEN	
TGF-β1	Mouse	NM_011577	QIAGEN	
α-SMA	Human	NM_001141945	QIAGEN	
Col1α1	Human	NM_000088	QIAGEN	
E-cadherin	Human	NM_ 004360	QIAGEN	
Fn-1	Human	NM_002026	QIAGEN	
GAPDH	Human	NM_001256799	QIAGEN	
N-cadherin	Human	NM_001042572	QIAGEN	
p16	Human	NM_000077	QIAGEN	
p21	Human	NM_000389	QIAGEN	
S100a4	Human	NM_002961	QIAGEN	
TGF-β1	Human	NM_000660	QIAGEN	
vimentin	Human	NM_003380	QIAGEN	

Supplemental Table 2: Characteristics of human control and PSC samples.

Group	No.	Diagnosis	Age	Gender	Ethnicity	Cirrhosis	Sample Type
Control	S1	Normal	N/A	N/A	N/A	No	Total liver
Control	S2	Normal	N/A	N/A	N/A	No	Total liver
Control	S 3	Normal	N/A	N/A	N/A	No	Total liver
Control	S4	Normal	N/A	N/A	N/A	No	Total liver
Control	S5	Normal	N/A	N/A	N/A	No	Total liver
Control	S6	Normal	N/A	N/A	N/A	No	FFPE liver sections
PSC	S1	Late stage PSC	60	Male	Caucasian	N/A	Total liver
PSC	S2	Early stage PSC	N/A	N/A	Caucasian	N/A	Total liver
PSC	S3	Early stage PSC	57	Male	Caucasian	N/A	Total liver
PSC	S4	Early stage PSC	33	Male	Caucasian	N/A	Total liver
PSC	S5	Early stage PSC	47	Female	Caucasian	N/A	Total liver

PSC	S6	Early stage PSC	42	Male	Caucasian	N/A	Total liver
PSC	S 7	Early stage PSC	63	Male	Caucasian	N/A	Total liver
PSC	S8	Stage I PSC	N/A	N/A	N/A	N/A	FFPE liver sections
PSC	S9	Stage IV PSC	N/A	N/A	N/A	N/A	FFPE liver sections

FFPE = formalin fixed paraffin embedded; N/A = Not available; PSC = Primary Sclerosing Cholangitis. Table outlining the characteristics of human control and PSC samples.